In 2026, Pharmacists Will Be Driving Change Across the Care Continuum

Under the leadership of new editor in chief Madeline Camejo, PharmD, MS, CPEL, chief pharmacy officer and vice president at Baptist Health South Florida, Pharmacy Practice in Focus: Health Systems enters 2026 with renewed commitment to showcasing the pharmacist’s expanding impact across rapidly evolving areas of care. Across different focus areas, her editorial direction will highlight how pharmacists advance evidence-based practice, optimize complex therapies, and close critical gaps in patient care.

In the Infectious Disease Focus, the use of intravenous push (IVP) administration of antimicrobials has gained renewed momentum across care settings because of its operational efficiency, reduced fluid use, and suitability for rapid or self-administered therapy. However, its use requires careful consideration of medication-specific safety and pharmacologic factors. Data from studies show IVP provides comparable outcomes to traditional infusions while shortening administration time and conserving supplies amid fluid shortages. Regardless, pharmacists must weigh infection severity and pharmacokinetic considerations to promote optimal therapeutic outcomes.

Data from the 2025 American Heart Association Scientific Sessions highlight the crucial role of pharmacists in helping patients achieve low-density lipoprotein cholesterol (LDL-C) goals through both virtual and in-person multidisciplinary care models, particularly for those at high risk of atherosclerotic cardiovascular disease (ASCVD). A pharmacist-led virtual clinic significantly improved lipid management after acute coronary syndrome by optimizing therapy escalation and providing adherence support. Within a Veterans Affairs system, pharmacist-guided interventions led to higher rates of LDL-C goal attainment and medication adherence compared with usual care. This shows that integrating pharmacists into cardiovascular care—especially in underserved populations—enhances lipid control, strengthens adherence, and supports more effective secondary prevention of ASCVD.

The role of pharmacists continues to expand in depth, scope, and impact across the health care landscape. As therapies grow more complex and health systems face ongoing operational and access challenges, the pharmacist’s ability to bridge gaps, individualize care, and drive guideline-aligned practice is more essential than ever. As we move into 2026, our commitment remains clear: Empowering pharmacists with the tools, evidence, and support they need will champion their role at the center of every care team.

Mike Hennessy Jr

Chairman & CEO, MJH Life Sciences^®